Seong YS - Search Results

1

Beta-Transducin Repeats-Containing Proteins as an Anticancer Target.

Kim DJ, Yi YW, Seong YS. Kim DJ, et al. Among authors: seong ys. Cancers (Basel). 2023 Aug 24;15(17):4248. doi: 10.3390/cancers15174248. Cancers (Basel). 2023. PMID: 37686524 Free PMC article. Review.

2

Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells.

You KS, Yi YW, Cho J, Seong YS. You KS, et al. Among authors: seong ys. Cancers (Basel). 2021 Mar 10;13(6):1205. doi: 10.3390/cancers13061205. Cancers (Basel). 2021. PMID: 33801977 Free PMC article.

3

Inhibition of IκB Kinase Is a Potential Therapeutic Strategy to Circumvent Resistance to Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Cells.

Yi YW, You KS, Han S, Ha IJ, Park JS, Lee SG, Seong YS. Yi YW, et al. Among authors: seong ys. Cancers (Basel). 2022 Oct 24;14(21):5215. doi: 10.3390/cancers14215215. Cancers (Basel). 2022. PMID: 36358633 Free PMC article.

4

Doxycycline potentiates the anti-proliferation effects of gemcitabine in pancreatic cancer cells.

Yi YW, Park NY, Park JI, Seong YS, Hong YB. Yi YW, et al. Among authors: seong ys. Am J Cancer Res. 2021 Jul 15;11(7):3515-3536. eCollection 2021. Am J Cancer Res. 2021. PMID: 34354858 Free PMC article.

5

Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?

Yi YW, You KS, Park JS, Lee SG, Seong YS. Yi YW, et al. Among authors: seong ys. Int J Mol Sci. 2021 Dec 21;23(1):48. doi: 10.3390/ijms23010048. Int J Mol Sci. 2021. PMID: 35008473 Free PMC article. Review.

6

HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction.

Kang HJ, Yi YW, Hong YB, Kim HJ, Jang YJ, Seong YS, Bae I. Kang HJ, et al. Among authors: seong ys. Sci Rep. 2014 Dec 3;4:7201. doi: 10.1038/srep07201. Sci Rep. 2014. PMID: 25467193 Free PMC article.

7

β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells.

Yi YW, Kang HJ, Bae EJ, Oh S, Seong YS, Bae I. Yi YW, et al. Among authors: seong ys. Exp Mol Med. 2015 Feb 27;47(2):e143. doi: 10.1038/emm.2014.127. Exp Mol Med. 2015. PMID: 25721419 Free PMC article.

8

Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.

You KS, Yi YW, Kwak SJ, Seong YS. You KS, et al. Among authors: seong ys. Int J Oncol. 2018 Mar;52(3):828-840. doi: 10.3892/ijo.2018.4244. Epub 2018 Jan 15. Int J Oncol. 2018. PMID: 29344641

9

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.

You KS, Yi YW, Cho J, Park JS, Seong YS. You KS, et al. Among authors: seong ys. Pharmaceuticals (Basel). 2021 Jun 18;14(6):589. doi: 10.3390/ph14060589. Pharmaceuticals (Basel). 2021. PMID: 34207383 Free PMC article. Review.

10

OSGIN1 is a novel TUBB3 regulator that promotes tumor progression and gefitinib resistance in non-small cell lung cancer.

Xie X, Laster KV, Li J, Nie W, Yi YW, Liu K, Seong YS, Dong Z, Kim DJ. Xie X, et al. Among authors: seong ys. Cell Mol Life Sci. 2023 Aug 30;80(9):272. doi: 10.1007/s00018-023-04931-4. Cell Mol Life Sci. 2023. PMID: 37646890 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters